Health Canada approves Telix’s Illuccix label expansion
Health Canada has expanded the approved use of Telix Pharmaceuticals' Illuccix for patient selection in PSMA targeted radionuclide therapy.
Health Canada has expanded the approved use of Telix Pharmaceuticals' Illuccix for patient selection in PSMA targeted radionuclide therapy.
What's Your Reaction?
